TSX · Biotechnology · CAD
Helix BioPharma Corp. (HBP.TO) Stock Analysis
Helix BioPharma Corp. (HBP.TO) is a Biotechnology stock listed on TSX and quoted in Canadian Dollar.
Last Updated: October 21, 2026
Price History
No price data available
Hover for the daily close. The dotted line marks the period open.
HBP.TO Key Statistics
As of Oct 21, 2026Trading
- Open
- CA$0.91
- Previous Close
- CA$0.98
- Day's Range
- 0.90–0.98
- 52-Week Range
- 0.85–2.60
- Volume
- 9.50K
- BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
- −0.14
Valuation
- Market Cap
- CA$74.85M
- P/E Ratio
- unprofitable
- EPS (ttm)Profit attributable to each share over the last twelve months.
- −0.04
Financials (FY)
- Revenue (FY)
- CA$0.00
- Net Income (FY)
- −CA$9.26M
- Shares Outstanding
- 76.38M
- 1-Year Return
- −59.34%
Dividend and dates
- Earnings Date
- October 29, 2026estimated
- Avg Volume
- 7.33K
Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.
Key facts
As of October 21, 2026, HBP.TO closed at CA$0.98, −59.34% over 1 year.
Helix BioPharma Corp. (HBP.TO) has a market capitalization of CA$74.85M.
In fiscal 2024, HBP.TO reported revenue of CA$0.00.
HBP.TO Stock Return by Calendar Year
Helix BioPharma Corp. (HBP.TO) 10-year return: what CA$10,000 became
- 1 year
- CA$10,000 CA$4,066
- −59.34%
- 5 years
- CA$10,000 CA$3,843
- −61.57%
- 10 years
- CA$10,000 CA$1,233
- −87.67%
If you had invested CA$10,000 in Helix BioPharma Corp. (HBP.TO) 10 years ago, at the close on October 21, 2016, it would have been worth CA$1,233 at the close on October 21, 2026: −87.67% in total, −18.89% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.
Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.
| Year | Return |
|---|---|
| 2026 (partial year) | −58.65% |
| 2025 | +166.29% |
| 2024 | −15.24% |
| 2023 | −4.55% |
| 2022 | −26.67% |
| 2021 | −40.00% |
| 2020 | −62.69% |
| 2019 | +152.83% |
| 2018 | −43.62% |
| 2017 | −38.96% |
| 2016 (partial year) | −22.22% |
As of October 21, 2026.
HBP.TO Revenue and Earnings by Fiscal Year
FY ends July| Fiscal year | Revenue | Net income | Net margin |
|---|---|---|---|
| 2024 | CA$0.00 | −CA$9.26M | — |
| 2023 | CA$0.00 | −CA$6.29M | — |
| 2022 | CA$0.00 | −CA$6.56M | — |
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| 2024 | CA$0.00 | — | −CA$9.24M | −CA$9.26M | — |
| 2023 | CA$0.00 | — | −CA$6.33M | −CA$6.29M | — |
| 2022 | CA$0.00 | — | −CA$6.04M | −CA$6.56M | — |
Annual figures as reported, in the company's reporting currency. As of July 31, 2024.
Analysis
Data-derivedEvery figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.
Related Biotechnology Stocks
Vertex Pharmaceuticals Incorporated
$132.95B
MRNAModerna, Inc.
$98.14B
REGNRegeneron Pharmaceuticals, Inc.
$82.95B
ARGXargenx SE
$55.97B
ONCBeOne Medicines AG
$43.97B
RVMDRevolution Medicines, Inc.
$41.64B
Popular Healthcare Stocks
Eli Lilly and Company
$1.13T
JNJJohnson & Johnson
$621.22B
ABBVAbbVie Inc.
$503.27B
UNHUnitedHealth Group Incorporated
$374.30B
MRKMerck & Co., Inc.
$369.78B